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Abstract
Background: Tuberculosis (TB) is a global concern for both developing and developed countries. Currently it
becomes more complex due to increasing levels of drug resistance and HIV co-infection. Delayed diagnosis and
high case load are major factors contributing to continued transmission and failure to the treatment outcome. The
study was conducted to determine the profile and treatment outcomes of TB patients at Felege-Hiwot Referral
Hospital.
Methods: We analyzed the records of 1761 TB patients registered for treatment in Felege Hiwot Referral Hospital
from July 2010 to June 2015. Data on patients’ socio-demographic characteristics, type of TB, HIV status and
treatment outcome were analysed. Descriptive statistics and binary logistic regression models were used to present
data. The odds ratio and the 95 % confidence intervals were calculated. A p-value of < 0.05 was considered
statistical significant.
Results: The proportion of smear positive, smear-negative and extra-pulmonary TB were 205 (11.6 %), 548 (31.1 %)
and 1008 (57.2 %), respectively. The overall treatment success rate accounts 542(80.8 %) with unsuccessful
treatment of 129(19.2 %). The treatment outcome varied by the years from 68.9 to 97.4 %. Among tuberculosis
patients, 459(26.1 %) of them were HIV positive. Being HIV positive (AOR = 4.29, 95 % CI, 2.20–8.37 P = 0.001),
retreatment (AOR = 5.32, 95 % CI, 1.92–14.3, P = 0.001), rural residency (AOR = 18.0, 95 % CI, 9.06–37.82, P = 0.001)
and the age group of 15–24 years (AOR = 2.91, 95%CI, 1.00–8.45, P = 0.04) showed statistical significant association
for poor treatment outcome.
Conclusions: In the studied region, the overall treatment success rate was still below the WHO target of success
rate, 85 %. However, the trend of treatment success rate showed a promising increment. Patients at high risk of
unsuccessful treatment outcome should be identified early and given additional follow-up, medical intervention
and social support.
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Background
Tuberculosis (TB) is a global concern and recently it
becomes more complex due to increasing levels of drug
resistance and HIV co-infection [1]. Developing countries,
like Ethiopia, have high burden of TB, one of the most
serious public health challenges [2]. An increased inci-
dence of TB is found mostly in Africa and Asia, where
the highest prevalence of co-infection with HIV is re-
ported [3, 4]. Ethiopia is highly affected by TB and it is
ranked 7th among the 22 high TB burden countries by
the world health Organization (WHO) [5]. In develop-
ing countries, there is high burden of TB and HIV, de-
layed diagnosis which is a major contributing factor to
the continued transmission and failure to the treatment
outcome [6]. Patient non-adherence to the anti-TB
treatment is also interpreted as a failure of the health
care system [7].
Currently, Ethiopia reports treatment success and case
detection rates of 83 and 62 % of all forms of TB, respect-
ively (8). The TB control program in Ethiopia introduced
the standardized Directly Observed Treatment, Short
Course (DOTS) as a pilot programme in 1992 and at
Felege Hiwot Referral Hospital in 2000. The standardized
DOTS/Stop TB Strategy geographical coverage reached at
100 %. Moreover, at the health facility level, it reached
95 % [8]. However, reports showed that the treatment
outcome of TB patients treated under the DOTS pro-
gram was unsatisfactory [9]. Reports showed that sev-
eral factors such as male sex, age ≥ 65 years, drug
resistance, HIV co-infection, previously treated TB cases
and cavitation affect treatment success rate [10–16]. In
addition, various social, behavioral, and economic charac-
teristics have been found to be associated with lower treat-
ment success rate [14, 15]. Although the purpose of TB
treatment is curing the patient, preventing the spread of
TB infection and preventing the emergence of new drug
resistant strains, these plans are not achieved in Ethiopia.
There is a limited report on the DOTS experiences in
Northwest Ethiopia. This study is aimed at evaluating the
treatment outcome and associated risk factors for new
smear positive pulmonary TB (PTB+), extra pulmonary TB
(EPTB) and smear negative pulmonary TB (PTB-) cases
registered at Felege-Hiwot Referral Hospital (FHRH)
DOTS programme.
Methods
Study design, period and population
With a cross sectional retrospective study, all patients
diagnosed and treated during the period of July 2010
to June 2015 at FHRH were included in the study to assess
TB profile and treatment outcome. The hospital is found
in Bahir Dar, the capital city of Amhara National Regional
State, which is located 565 km away from Addis Ababa.
The current TB diagnosis and treatment strategy in
Ethiopia is the stop TB or DOTS strategy. Sputum sam-
ples were collected using spot-morning-spot strategy
and other clinical samples were collected depending
on the site of infection. The collected clinical specimens
were examined using the standard Ziehl-Neelsen (ZN)
acid fast bacilli (AFB) staining technique, Fluorescent
Microscopy (FM) or GeneXpert MTB/RIF assay [8].
Moreover, imaging and pathological techniques might
have been used for those PTB- and EPTB cases before
being admitted to DOTS programme. For those diag-
nosed with new active TB, the standard TB treatment
regimen such as, 2 months of intensive treatment with
Rifampicin, Isoniazid, Pyrazinamide and Ethambutol
(2RHZE) followed by 4 months of continuation phase
with Rifampicin and Isoniazid (4RH). Likewise for those
retreated cases, the intensive phase contains 2 months
of streptomycin and the combination of HRZE drugs
(2S (HRZE)) and additional 1 month of treatment with-
out streptomycin; 1 (HRZE). Then the continuation
phase contains 5 months of treatment with the combin-
ation of RH and E; 5 (HR) E [17, 18].
Human immunodeficiency virus test
The anti-HIV antibody test was used for the screen-
ing of HIV/AIDS and it was done according to the
manufacturer’s instruction (rapid test currently used in
national algorithm for Ethiopia; KHB, Shanghai Kehua
Bio-engineering Co., Ltd. China) for screening and posi-
tive samples were re-tested with STAT-PACK (Chembio
HIV 1/2 STAT-PAK™ Assay, CHEMBIO DIAGNOSTIC
SYSTEMS, INC., MEDFORD, NY, USA). Samples giving
discordant results in the two tests were re-examined using
the tiebreaker (Uni-Gold HIV, Trinity Biotech PLC,
Co. Wicklow, Ireland).
Operational definitions
According to the standard definitions of the National
Tuberculosis and Leprosy Control Program guideline
(NLCP) adopted from the WHO [19], the following clinical
case and treatment outcome definitions were used:
– Cured: A patient with bacteriologically confirmed
pulmonary TB at the beginning of treatment who
was smear or culture-negative in the last month of
treatment
– Treatment completed: A patient with TB who
completed treatment without evidence of failure, but
with no record of sputum smear or culture results,
in the last month of treatment.
– Successful treatment outcome: If PTB patients
were cured (i.e., negative smear microscopy at the
end of treatment and on at least one previous
follow-up test) or completed treatment with reso-
lution of symptoms.
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– Unsuccessful treatment outcome: If treatment
of PTB/EPTB/ patients resulted in treatment failure
(i.e., remaining smear-positive after 5 months of
treatment), default (i.e., patients who interrupted
their treatment for two consecutive months or
more after registration), or death.
– Died: A TB patient who died from any cause during
treatment.
– Failure: A TB patient whose sputum smear or
culture is positive at month 5 or later during
treatment.
– Lost to follow-up: A TB patient whose treatment
was interrupted for two consecutive months or
more.
– Pulmonary TB, smear-positive: A patient with at
least two sputum specimens which were positive for
AFB by microscopy, or a patient with only one
sputum specimen which was positive for AFB by
microscopy, and chest radiographic abnormalities
consistent with active pulmonary TB.
– Pulmonary TB, smear-negative: A patient with
symptoms suggestive of TB, with at least two
sputum specimens which were negative for AFB by
microscopy, and with chest radiographic
abnormalities consistent with active pulmonary TB
(including interstitial or miliary abnormal images),
or a patient with two sets of at least two sputum
specimens taken at least two weeks apart, and
which were negative for AFB by microscopy, and
radiographic abnormalities consistent with
pulmonary TB and lack of clinical response to
one week of broad spectrum antibiotic therapy.
– Extra pulmonary TB: This included TB of organs
other than the lungs, such as lymph nodes,
abdomen, genitourinary tract, skin, joints and
bones, meninges, etc. Diagnosis of EPTB was
based on fine needle aspiration cytology or
biochemical analyses of cerebrospinal/pleural/
ascitic fluid or histopathological examination or
strong clinical evidence consistent with active
EPTB, followed by a decision of a clinician to
treat with a full course of anti-tuberculosis
chemotherapy. In all the cases of EPTB, sputum
examinations and chest radiographs were used to
investigate the involvement of lung parenchyma.
Inclusion and exclusion criteria
All TB patients with complete data like age, sex, treatment
outcome were included. Missing of either of these vari-
ables were the exclusion criteria.
Data collection and tools
Demographic and clinical data such as age, sex, type
of TB, TB treatment outcome, status of HIV infection,
Co-trimoxazole prophylaxis (CPT) and antiretroviral ther-
apy (ART) status were retrieved from TB registry using
data extraction sheet.
Data analysis
All data were entered in to Epi Info 3.1 and analysed
using SPSS statistical software package (IBM Corp. Re-
leased 2011. IBM SPSS Statistics for Windows, Version
20.0. Armonk, NY: IBM Corp.). Descriptive statistics was
used to determine differences within the data of vari-
ables. All explanatory variables with a p value ≤0.2 in the
bivariate analysis were included in the multivariate logis-
tic regression model to identify independent predictive
variables. Odds ratio (OR) and 95 % confidence intervals
(CI) were calculated and the results were considered sta-
tistically significant at p < 0.05.
Results
Socio demographic characteristics of patients
A total of 1761 patients’ document has been reviewed.
Of which 1054 (59.9 %) were males. The highest num-
bers of study participants were urban dwellers, 1142
(64.8 %). The mean age of the study subjects was 28.11
(SD. ±14.25). The proportion of smear positive, smear-
negative and extra-pulmonary TB was 205 (11.6 %), 548
(31.1 %) and 1008 (57.2 %), respectively. The age group
15–34 years accounted more than half of the study sub-
jects and the peak age group of 15–24 years presented
about one-third of the total TB patients, (Table 1).
Tuberculosis treatment outcomes
Of the total TB patients, 1090 (61.9 %) were transferred
out to other health facilities. Thus, their treatment out-
come status were not known and excluded from the
treatment outcome analysis. Of the total TB patients
with known treatment outcome, the treatment success
rate was 542(80.8 %) with unsuccessful treatment of
129(19.2 %). The unsuccessful treatment outcomes
shared to 30(4.5 %) defaulted, 98(14.6 %) died and
1(0.001 %) failed. Among all TB patients, 459(26.1 %) of
them were sero-positive for HIV/AIDS (Table 1). The
majority of TB patients who have unsuccessful treat-
ment outcome were among HIV positive patients, 70
(38.7 %) (Fig. 1). The death rate of PTB+, PTB- and
EPTB were 13(13.3 %), 29(29.6 %) and 56(57.1 %), re-
spectively (Table 1).
Trend of tuberculosis treatment outcomes
Over a period of 5 years, the treatment outcomes under
DOTS program of TB patients varied from years to
years. The successful treatment outcomes from 2010 to
2012 were decreased from 83.3 to 68.9 %. But, from
2013 onwards it showed an increase of successful
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treatment outcomes from 80.1 to 97.4 %. The detail in-
formation is described in Fig. 2.
Factors associated with TB treatment success rate
In the multivariate logistic regression model, HIV posi-
tive TB patients were about 4 times more likely to have
unsuccessful TB treatment than whose sero-status was
unknown (AOR = 4.29, 95 % CI, 2.20–8.37 P = 0.001),
while a decreased treatment success rate was observed
with the patients’ age group 15–24 years (AOR = 2.91,
95 % CI, 1.00–8.45, P = 0.04). Furthermore, a lower treat-
ment success rate was documented among retreated TB
patients (AOR = 5.32, 95 % CI, 1.92–14.3, P = 0.001). On
the other hand, patients from urban areas had a signifi-
cantly higher treatment success rate compared to cases
from rural locations (AOR = 18.0, 95 % CI, 9.06–37.82,
P = 0.001) (Table 2).
Discussion
In our study with the microscopically confirmed TB
cases in FHRH DOTS clinic, we observed a successful
outcome of TB treatment in 80.8 % of the patients,
which is less than the target level set by the WHO for
successful outcomes of 85 %. However, it is comparable
to the national report of the successful outcome of TB
treatment in Ethiopia (83 %) [8]. Moreover the treatment
success rate among the 22-high TB burden countries
varied from 60 to 93 %, with an average of 83 % [4, 8,
20]. On the other hand, our finding is still below other
findings reported in Tigray, Ethiopia, 89.2 % [21] and in
Spain, 89 % [22]. But the treatment success in our study
was better than the studies conducted in Southern
Ethiopia, 49 % [23], and Finland, 70.1 % [24].
The treatment success rate was poor in 2010–2012,
although a prominent improvement was observed in 2013–
2015. This improvement could be due to an improved ac-
cess to TB control services, particularly community-based
interventions, the expansion of TB treatment centers and a
regimen change of the continuation phase to RH, which
lasts 4 months. This finding is supported by the study con-
ducted at the Southern Ethiopia [25].
The proportion of PTB+, PTB− and EPTB were 205
(11.6 %), 548 (31.1 %) and 1008 (57.2 %), respectively. This
is in line with other studies reported elsewhere in the
country [9, 21, 26, 27]. However, the vice versa result
has been declared from Gambella region [28]. The high
level of EPTB in this study might be due to the over
diagnosis of EPTB using clinical data, imaging and
pathologic evidence. Moreover, the large number of
PTB− and EPTB cases might be due to the high pro-
portion of TB - HIV co-infection which is quite com-
mon among these patients in a high TB and HIV
burden setting [29].
Unsuccessful treatment outcome was more frequent
(AOR = 5.32, 95 % CI, 1.92–14.3, P = 0.001) among
retreated cases than among those newly treated. This
was similar to the study conducted in Tigray region,
Ethiopia [21]. Among TB patients, the majority of
them were EPTB cases and the most unsuccessful
outcome of TB treatment at (23.2 %) was observed in
these patients.
In this study, the proportion of TB/HIV co-infection
was found to be 459 (26.0 %). The majority of HIV
Table 1 Demographic characteristics and HIV status of
Tuberculosis Patients at FHRH, Ethiopia, 2015










Female 89 (12.6) 204 (28.9) 414 (58.4) 707 (100)
Male 116 (11.0) 344 (32.6) 594 (56.4) 1054 (100)
Age
<=14 5 (2.3) 78 (35.6) 136 (62.1) 219 (100)
15–24 102 (16.9) 185 (30.7) 316 (52.4) 603 (100)
25–34 58 (13.1) 126 (28.5) 258 (58.4) 442 (100)
35–44 28 (10.9) 80 (31.0) 150 (58.1) 258 (100)
45–54 4 (3.1) 42 (32.8) 82 (64.1) 128 (100)
≥55 8 (7.2) 37 (33.3) 66 (59.5) 111 (100)
Residence:
Rural 163 (14.3) 382 (33.5) 597 (52.3) 1142 (100)
Urban 42 (6.8) 166 (26.8) 411 (66.4) 619 (100)
HIV Status:
Positive 44 (9.6) 164 (35.7) 251 (54.7) 459 (100)
Negative 154 (12.5) 364 (29.5) 717 (58.1) 1235 (100)
Unknown 7 (10.4) 20 (29.9) 40 (59.7) 67 (100)
History of TB
New 154 (9.8) 497 (31.8) 914 (58.4) 1565(100)
Retreated 13 (40.6) 6 (18.6) 13 (40.6) 32 (100)
Transfer in 36 (23.4) 44 (28.6) 74 (48.1) 154 (100)
Other 2 (20.0) 1 (10.0) 7 (70.0) 10 (100)
Treatment out- come
Cured 85 (98.8) 0 (0.0) 1 (1.2) 86 (100)
Complete 18 (3.9) 187 (41.0) 251 (55.0) 456 (100)
Died 13 (13.3) 29 (29.6) 56 (57.1) 98 (100)
Failer 1 (100) 0 (0.0) 0 (0.0) 1 (100)
Loss of follow up 3 (10.0) 7 (23.3) 20 (66.7) 30 (100)
Transfer out 85 (7.8) 325 (29.8) 680 (62.4) 1090 (100)
CPT Took
Yes 33 (11.5) 97 (33.8) 157 (54.7) 287(100)
No 172 (11.7) 451 (30.6) 851 (57.7) 1474(100)
PTB+: Smear positive pulmonary tuberculosis, PTB−: Smear negative
pulmonary tuberculosis, EPTB: Extra-pulmonary tuberculosis
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positive patients (29.9 %) were among PTB- patients, in-
dicating that HIV testing before treatment is crucial.
This finding was higher than the study conducted in
India [30]. However, previous studies conducted at
Gondar University Hospital showed that high propor-
tions (52.5 %) of TB patients were co-infected with HIV.
[31, 32]. Moreover, multivariate logistic regression analysis
showed that, being HIV positive was one of the independ-
ently associated risk factor for poor treatment outcome
(AOR= 4.29, 95 % CI, 2.20–8.37, P = 0.001). This finding
was in agreement to other study in Zimbabwe [33]. This
might be due to the low level of immunity and drug
mal-absorption among HIV patients. This is supported by
other studies [27, 34, 35]. Our results indicate the ne-
cessity of strengthening interventions to reduce TB-HIV
co-infection in the study region.
It is well studied that retreated patients are more vulner-
able for the development of MDR-TB and poor treatment
outcome [36]. In our finding, unsuccessful treatment out-
come was higher among retreated TB cases than new TB
patients (AOR = 5.32, 95 % CI, 1.92–14.3, P = 0.001). Simi-
lar finding was declared from the study conducted in
South India [37]. Rural residence was also significantly as-
sociated with the poor treatment outcome of TB patients
(AOR = 18.0, 95 % CI, 9.06–37.82, P = 0.001). The same
finding was reported by Hailu MD et al. [25]. This might
be due to awareness differences between rural and urban
populations. Tuberculosis patients in the age group 15–24
years were more likely for the unsuccessful treatment out-
come than other age group (AOR = 2.91, 95 % CI, 1.00–
8.45, P = 0.04). However, Berhe G et al. in 2012 [21] and
Tessema et al. in 2009 [9] reported different pattern. This
Fig. 1 The distribution of tuberculosis treatment outcome based on of types of TB and HIV status among TB patients at FHRH, 2015
Fig. 2 The 5 years trend of TB treatment outcome rate among TB patients at FHRH, 2015
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finding is unusual and it is recommended to be more
studied. In this study, there was no difference in success
rates by sex. This was also supported by other studies con-
ducted elsewhere in Ethiopia [21, 38].
In this study, we observed a default rate at 4.5 %,
which was found to be lower compared to other studies
in Ethiopia, 18 % [9], Switzerland, 16 % [39], Germany,
10 % [40], and Sweden, 7 % [41]. In Ethiopia a standardized
TB prevention and control programme is incorporating
DOTS. This might be one of the reasons for the smaller
proportions of default rate in this study. However, the
presence of default is a major public health problem
that the patients may remain infectious and even de-
velop MDR-TB.
Conclusions
In conclusion, the overall treatment success rate in the
current study (80.8 %) was still below the WHO target
of success rate (85 %). However, the prominent improve-
ment has been observed in 2013–2015. In the studied re-
gion, HIV-TB co-infection, young age (15–24 years), rural
residence and retreatment of patients were found to be
predictors for the poor treatment outcome. Based on our
finding, we recommend that patients at high risk of
Table 2 Association of poor treatment outcome with possible predictors among tuberculosis patients at FHRH, 2015






Female 63 (24.4) 195 (75.6) 0.58 (0.4–0.87), 0.007 0.26 (0.06–1.13),0.26
Male 66 (16.0) 347 (84.0) 1 1
Age
<=14 6 (12.5) 42 (87.5) 2.57 (0.76–8.71),0.13 2.4 (0.63–9.12),0.20
15–24 24 (8.3) 266 (91.7) 4.08 (1.56–10.68), 0.04 2.91 (1.00–8.45),0.04
25–34 47 (27.2) 126 (72.8) 0.98 (0.39–2.50), 0.98 1.22 (0.43–3.46),0.70
35–44 30 (31.9) 64 (68.1) 0.78 (0.29–2.07),0.62 1.10 (0.37–3.29),0.86
45–54 15 (37.5) 25 (62.5) 0.61 (0.20–1.80), 0.37 1.34 (0.39–4.84),0.61
≥55 7 (26.9) 19 (73.1) 1 1
Residence
Rural 42 (72.4) 16 (27.6) 15.87 (8.55–29.47), 0.00 18.0 (9.06–37.82),0.001
Urban 87 (14.2) 526 (85.8) 1 1
Types of TB
PTB+ 17 (14.2) 103 (85.8) 1.83 (1.03–3.24),0.03 1.90 (0.92–3.90),0.08
PTB- 36 (16.1) 187 (83.9) 1.57 (1.01–2.43),0.04 1.46 (0.86–2.46),0.154
EPTB 76 (23.2) 252 (76.8) 1 1
HIV Status
Positive 70 (38.7) 111 (61.3) 4.6 (3.06–6.93),0.001 4.29 (2.20–8.37), 0.001
Negative 56 (12.0) 412 (88.0) 4.62 (1.33–16.02),0.016 3.70 (0.88–16.17),0.07
Unknown 3 (13.6) 19 (86.4) 1 1
History of TB
New 117 (21.9) 418 (78.1) 1 1
Retreated 7 (36.8) 12 (63.2) 6.27 (2.50–15.71),0.001 5.32 (1.92–14.3),0.001
Transfer in 5 (4.5) 107 (95.5) 10.48 (0.18–1.24),0.13 0.23 (0.08–0.70),0.01
Other 0 (0) 5 (100)
CPT Took
Yes 42 (34.4) 80 (65.6) 2.79 (1.80–4.32),0.001 1.32 (0.65–2.61),0.45
No 87 (15.8) 462 (84.2) 1 1
PTB+: Smear positive pulmonary tuberculosis, PTB−: Smear negative pulmonary tuberculosis, EPTB: Extra-pulmonary tuberculosis, AOR: adjusted odds ratio, COR :
cruds odds ratio
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unsuccessful treatment outcome should be identified early
and given additional follow-up, medical intervention and
social support.
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